Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 29

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 29
---
worldwide license to use manufacturing information and non-clinical and clinical data that the U.S. Army possesses relating to use of
Tafenoquine for all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. We have submitted patent applications
in the United States and certain foreign jurisdictions for use of Tafenoquine for COVID-19, fungal lung infections, tick-borne diseases,
and other infectious and non-infectious diseases in which induction of host cytokines/inflammation is a component of the disease process.
The United States Patent and Trademark Office (“USPTO”) recently allowed our first COVID-19 patent for Tafenoquine. We have
optioned or licensed patents involving Celgosivir for the treatment and prevention of Dengue (from the National University of Singapore),
COVID-19 & Zika (Florida State University), and have pending patent applications related to Celgosivir for RSV. We have optioned
or own manufacturing methods related to Celgosivir. A detailed list of our intellectual property is as follows:

Patents

    Title 
    Patent No. 
    Country 
    Status 
    US Patent Date 
    Application  No. 
    Estimated/ Anticipated
    Expiration Date
  
    Dosing Regimen For Use Of Celgosivir As An Antiviral
    Therapeutic For Dengue Virus Infections 
    2013203400 
    Australia 

    2013203400+ 
    10-April-2033*
  
    Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue 
    2014228035 
    Australia 

    2014228035 
    14-Mar-2034*
  
    Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue 
    MY-170991-A 
    Malaysia 

    PI2015002372 
    14-Mar-2034*
  
    Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue 
    378015 
    Mexico 

    MX/a/2015/013115 
    14-Mar-2034*
  
    Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue 
    11201507254V 
    Singapore 

    11201507254V 
    14-Mar-2034*
  
    Novel Dosing Regimens Of Celgosivir For The Treatment Of